Evidence map›Paper›PMID 36932282›Full record

ArticleWorld journal of urology2023

Status of

Yufan Tang, Xiaowei Ji, Qi Lin, Hang Huang, Honghui Zhu, Xixi Huang, Hui Xie, Wei Chen, Yuandi Zhuang

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Efficacy of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Pooled it
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yufan Tang *Department of Urology, Jiashan County First People's Hospital, Jiaxing, China.
Xiaowei Ji *Department of Nuclear Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Qi LinDepartment of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Hang HuangDepartment of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Honghui ZhuDepartment of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Xixi HuangDepartment of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Hui XieDepartment of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. xiehuiwenzhou@aliyun.com.
Wei ChenDepartment of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. wzmuchenwei@163.com.
Yuandi ZhuangDepartment of Radiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. viaviahei@163.com.ORCID http://orcid.org/0000-0002-7365-2531
Wenzhou Medical University · CNFirst Hospital of Jiaxing · CN

Funding

Natural Science Foundation of Zhejiang Province LQ20H050001Natural Science Foundation of Zhejiang Province LY20H160013
6 · The paper itself

Abstract

purposeTreatment of primary prostate cancer extremely depends on preoperative stage. The role of MATERIALS AND

methodsIn this retrospective study, all patients with prostate cancer who underwent mpMRI and

resultsUltimately, 130 patients were included in this study. In the preoperative judgment of EPE and SVI, mpMRI + PSMA-PET/CT had higher sensitivity and specificity. When predicting lymph node metastasis, PSMA-PET/CT was the best choice. The accuracy of mpMRI + PSMA-PET/CT and PSMA-PET/CT in the T and N stages, respectively, was affected by the least factors.

conclusionsBased on the combined results of mpMRI and

Indexed as

Multiparametric Magnetic Resonance ImagingProstatic NeoplasmsHumansMaleNiacinamideOligopeptidesPositron Emission Tomography Computed TomographyRetrospective StudiesNiacinamideOligopeptidesPSMA-100718F-1007-PSMA-PET/CTmpMRIPreoperative evaluationProstate cancer

Identifiers

PMID36932282
OpenAlexW4327747434

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.